These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8750263)

  • 1. Allogeneic bone marrow transplantation for primary myelofibrosis.
    Singhal S; Powles R; Treleaven J; Pollard C; Lumley H; Mehta J
    Bone Marrow Transplant; 1995 Dec; 16(6):743-6. PubMed ID: 8750263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility in women.
    Singhal S; Powles R; Treleaven J; Horton C; Swansbury GJ; Mehta J
    Bone Marrow Transplant; 1996 Dec; 18(6):1049-55. PubMed ID: 8971372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic bone marrow transplantation for children with histiocytic disorders: use of TBI and omission of etoposide in the conditioning regimen.
    Hale GA; Bowman LC; Woodard JP; Cunningham JM; Benaim E; Horwitz EM; Heslop HE; Krance RA; Leung W; Shearer PD; Handgretinger R
    Bone Marrow Transplant; 2003 Jun; 31(11):981-6. PubMed ID: 12774048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
    Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
    Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Allogeneic bone marrow transplantation for primary myelofibrosis after splenectomy].
    Sakashita C; Akiyama H; Mori S; Ohashi K; Sakamaki H
    Rinsho Ketsueki; 2000 Mar; 41(3):206-11. PubMed ID: 10774249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of allogeneic bone marrow transplantation using related donors stimulated with G-CSF.
    Isola LM; Scigliano E; Skerrett D; Shank B; Ross V; Najfeld V; Fruchtman S
    Bone Marrow Transplant; 1997 Dec; 20(12):1033-7. PubMed ID: 9466275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
    Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
    Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):416-9. PubMed ID: 14642179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma.
    Kamani N; August CS; Bunin N; Leahey A; Bayever E; Goldwein J; Zusman J; Evans AE; Angio GD
    Bone Marrow Transplant; 1996 Jun; 17(6):911-6. PubMed ID: 8807093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis.
    Snyder DS; Palmer J; Stein AS; Pullarkat V; Sahebi F; Cohen S; Vora N; Gaal K; Nakamura R; Forman SJ
    Biol Blood Marrow Transplant; 2006 Nov; 12(11):1161-8. PubMed ID: 17085309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation.
    Gordon BG; Warkentin PI; Strandjord SE; Abromowitch M; Bayever E; Harper JL; Coccia PF
    Bone Marrow Transplant; 1997 Jul; 20(1):5-10. PubMed ID: 9232249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute megakaryoblastic leukemia with massive myelofibrosis: complete remission and reversal of marrow fibrosis with allogeneic bone marrow transplantation as the only treatment.
    Bullorsky EO; Shanley CM; Stemmelin G; Venditti J; Lajous JR
    Bone Marrow Transplant; 1990 Dec; 6(6):449-52. PubMed ID: 2097015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation.
    Remberger M; Ringdén O; Ljungman P; Hägglund H; Winiarski J; Lönnqvist B; Aschan J
    Bone Marrow Transplant; 1998 Jul; 22(1):73-8. PubMed ID: 9678799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
    Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
    Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised study of allogeneic transplantation with stem cells from blood or bone marrow.
    Heldal D; Tjønnfjord G; Brinch L; Albrechtsen D; Egeland T; Steen R; Solheim BG; Evensen SA
    Bone Marrow Transplant; 2000 Jun; 25(11):1129-36. PubMed ID: 10849524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.
    Mehta J; Powles R; Treleaven J; Horton C; Tait D; Meller S; Pinkerton CR; Middleton G; Eisen T; Singhal S
    Bone Marrow Transplant; 1996 Oct; 18(4):741-6. PubMed ID: 8899189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.